Focus: KalVista is a public specialty pharmaceutical company focused on ophthalmology and neurology with 201-500 employees based in Framingham, MA. Currently generating ~$50M in revenue with a diversified pipeline focused on hereditary angioedema and diabetic macular edema.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow KalVista Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from KalVista Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for KalVista Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic ANDA formulation positioned for market entry; represents defensive strategy as branded AMICAR faces generic competition.
Multiple post-LOE ANDA entries indicate mature generic competition in this space with limited differentiation.
Post-LOE immunosuppressant ANDA; legacy product with mature market positioning and limited growth potential.
Cardiac ANDA in post-LOE phase; represents legacy portfolio diversification with stable but non-growth profile.
NDA-approved opioid in peak lifecycle; subject to regulatory scrutiny and market dynamics related to opioid scheduling/prescribing trends.
16 discontinued, 16 duplicate formulations not shown
8-K Filing: Monopar Therapeutics (MNPR) (CIK 0001645469) — EXHIBIT 99.1
EXHIBIT 99.1
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion - CHEManager
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion CHEManager
A Framingham biotech just became a $1.9B Italian acquisition. Here’s the drug behind it - MassLive.com
A Framingham biotech just became a $1.9B Italian acquisition. Here’s the drug behind it MassLive.com
Chiesi Group Completes $1.64 Billion Acquisition Of KalVista Pharmaceuticals - Pulse 2.0
Chiesi Group Completes $1.64 Billion Acquisition Of KalVista Pharmaceuticals Pulse 2.0
Chiesi Completes $1.9B KalVista Acquisition - AllSci
Chiesi Completes $1.9B KalVista Acquisition AllSci
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B - Contract Pharma
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B Contract Pharma
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo